Sanofi Takes Over Nuvaxovid Authorization in Canada, Expanding Vaccine Options
Sanofi has become the market authorization holder for Nuvaxovid, a non-mRNA COVID-19 vaccine, in Canada. This transition from Novavax to Sanofi is part of a strategic agreement signed in May 2024. Nuvaxovid, a protein-based vaccine, will be available for the 2026-2027 season, offering Canadians an alternative to mRNA vaccines. The vaccine has shown approximately 90% efficacy in preventing symptomatic COVID-19 and is suitable for individuals aged 12 and older. Sanofi's move underscores its commitment to diversifying vaccine options and addressing respiratory diseases in Canada. 
